The 36-month facility allows BioNexus to issue and sell registered shares of its common stock to ARC at its sole discretion. As compensation for ARC’s commitment, BioNexus issued 175,000 shares of …
BioNexus Gene Lab stock falls after securing $500M equity facility
view original post